Genmab A (GMAB) Cash from Operations Growth (3y) (2023 - 2026)
Powered by 
Analysis
Genmab A (GMAB) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -0.88% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 15.19% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | -0.27% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | -7.35% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 16.85% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 96.08% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -2.68% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -90.25% |
| Mar 31, 2024 | -43.04% |
| Mar 31, 2023 | 19.12% |